產(chǎn)品詳情
簡單介紹:
Lapatinib
詳情介紹:
Purpose | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug Capecitabine. Lapatinib is human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1) tyrosine kinases inhibitor. It binds to the intracellular phosphorylation domain to prevent receptor autophosphorylation upon ligand binding. |
Characteristics |
Source of Compound: synthetic Target: EGFR inhibitor, HER2 inhibitor Receptor: EGFR, ErbB2 Status: USP,INN |
Purification | All the products are sent with COA, HPLC and NMR inspection report to guarantee the quality. |
Purity | 98.50?% |
Formula | C29H26ClFN4O4S |
Solubility | Soluble in DMSO |
Molecular Weight | 581.06 g/mol |
CAS-No | 231277-92-2 |
Application Notes | Optimal working dilution should be determined by the investigator. |
Restrictions | For Research Use only |
Format | Solid |
Storage | -20 °C |
Storage Comment |
For the majority of compounds, they could be dissolved in DMSO or other organic solvent. Their stock solution can be stored at -20°C for up to 3 months and aliquoted for sampling convenience. Several freeze/thaw cycles should not damage the activity of our small molecule products. However, in many instances the aqueous solutions of some compounds need to be made fresh and cannot be stored. For these compounds, their solution should be prepared just before use and stored no longer than 24 hours. |
Expiry Date | 24 months |